What is the recommendation for prevention of HF?
For patients at risk of developing HF, natriuretic peptide biomarker based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or HF. New data suggest that natriuretic peptide biomarker screening and early intervention may prevent HF. Developing a standardized strategy to screen and intervene in patients at risk of HF can be difficult because of different definitions of HF risk, heterogeneity of prevalence in different populations, variable duration until clinical HF or left ventricular dysfunction develops, and variable interventions for risk factor modification or treatment.